Intraperitoneal FT536 in Recurrent Ovarian, Fallopian Tube, and Primary Peritoneal Cancer

Status: Recruiting

Eligibility Criteria

Sex: Female
Age Group: 18 years and over
This study is NOT accepting healthy volunteers

Inclusion Criteria:

- epithelial ovarian cancer, fallopian tube, or primary peritoneal cancer that has recurred after treatment (no limit to the maximum number of prior treatments) - must have received prior bevacizumab - if there is a BRCA mutation, must have received a prior PARP inhibitor - agree to the have an intraperitoneal catheter placed before the 1st dose of study drug - see link to clinicaltrials.gov for complete inclusion & exclusion criteria

Exclusion Criteria:

- women who are pregnant, breastfeeding or planning to become pregnant in the next 6 months - active autoimmune disease requiring systemic immunosuppressive therapy - history of severe asthma and currently on chronic medications (more than inhalers) - received enoblituzumab - CNS disease such as stroke, epilepsy, CNS vasculitis, or neurodegenerative disease or needing medications for these conditions in the past 2 years

Conditions & Interventions

Conditions:
Cancer, Women's Health
Keywords:
Clinics and Surgery Center (CSC), Fallopian Tube Cancer, Gynecologic Cancer, Ovarian Cancer, Primary Peritoneal Cavity Cancer

More Information

Description: FT536 is a type of cell product made up of “natural killer” or NK cells. NK cells are a type of immune blood cell that are known to attack cancer cells. FT536 is produced by growing cells that come from a healthy human donor. The primary purpose of this study is to identify a safe dose of FT536 cells when given alone (monotherapy).
Study Contact: Deanna Teoh - dkteoh@umn.edu
Principal Investigator: Melissa Geller, MD
Phase: PHASE1
IRB Number: STUDY00021809